
A source-linked scan of the September 18–25 capital-markets window: the 10-year Treasury above 5% and a 30-year at a 22-year high, SoftBank's record $11.1 billion high-yield sale, the Fed's stablecoin and bank-threshold proposals, BASF's approach to Evonik, and a $950 million CFTC fraud complaint.
| Area | Event | Stage and scale | Parties / advisers | Immediate read-through |
|---|---|---|---|---|
| IPO | National Stock Exchange of India (NSEI.BO) | Listed September 24, closed 1.85% above its offer price at ₹1,818, valuing the bourse at ₹4.5 trillion ($46.9 billion); the ₹225.6 billion ($2.3 billion) offering was entirely an offer for sale | — | India's second-largest IPO on record cleared, but the shares trade on a 43x fiscal 2026 multiple against rival BSE's 47x, reflecting concern about NSE's 68% revenue dependence on derivatives. 4 |
| IPO | Nscale (NSCL) | NYSE filing published September 18; targeting a valuation of about $30 billion; first-half revenue $140.6 million against a net loss of $1.02 billion | Goldman Sachs, J.P. Morgan and Morgan Stanley as lead underwriters | Only 5% of the 461,000 chips Nscale plans to deploy are operating, and $88 billion of its $103 billion contract value sits with two customers. 56 |
| IPO | Firmus | Term sheet issued September 21; institutional bookbuild opens October 6, prospectus lodges October 8, trading from October 22; seeking A$7 billion ($5 billion), up to A$5.5 billion with greenshoe | — | At A$7 billion this is the fourth-largest IPO globally this year and Australia's largest since Telstra in 1997 — the cleanest test yet of public-market appetite for data-centre construction. 7 |
| IPO | ADARx Pharmaceuticals (ADRX.O) | Priced September 25; 26.3 million shares at $17.00, upsized from 21.9 million and at the top of the range, for $446.3 million; opened at $22.10 | — | AbbVie's concurrent private placement of up to $100 million for roughly 4.9% post-IPO is the differentiator; top-line data on the Phase 3 lead drug is expected by end-2027. 8 |
| IPO | Holtec Nuclear | Registration statement withdrawn September 25, after the offering was suspended the previous week | — | The withdrawal, rather than the suspension, is what removes a $10.2 billion-valuation candidate from the 2026 pipeline. 9 |
| M&A | BASF / Evonik | Non-binding approach announced September 25 for all shares of Evonik; BASF market capitalisation €45.8 billion, Evonik €9.2 billion; RAG Foundation holds 43% of Evonik and was contacted | — | Evonik closed 7.2% higher and BASF 3.6% lower; the outcome is explicitly "open at this stage" and no discussion is under way, so treat this as an approach and not a deal. 10 |
| M&A | UniCredit and Credit Agricole / Banco BPM | Joint scenario floated with Italian authorities in recent conversations; would entail breaking up Banco BPM, with Credit Agricole taking roughly one third; no binding step taken | — | Credit Agricole already holds 29.3% of Banco BPM and its CFO said on September 23 that "nothing can be done without us". 1112 |
| M&A | Paramount Skydance / Warner Bros Discovery | States and Writers Guild litigation settled September 21; $7.5 billion incremental term B facility launched September 24, alongside plans to raise about $44.4 billion of additional secured debt; combined company expected to carry about $80 billion of debt | — | The settlement avoided a $7 million-a-day ticking fee past September 30, and the financing now has to clear a rate environment that moved against it during the week. 1314 |
| M&A | Warburg Pincus / Ingenia Communities | Second approach rejected September 21; A$2.06 billion ($1.47 billion) at A$5.05 cash per share, a 16.9% premium to the prior close and about 6.3% above the first offer | — | Citi analysts put a compelling all-cash range at A$5.25–A$5.50, so the gap that matters is roughly A$0.20–0.45 a share — and the bid is conditioned on Ingenia abandoning its A$711 million Peet purchase. 15 |
| M&A | Novo Nordisk / Nanexa | Global licensing deal announced after the September 24 close, worth up to about €1.17 billion ($1.33 billion); €615 million in upfront plus development and regulatory milestones, the balance in sales milestones | — | Nanexa shares rose about 122% and the structure splits value between near-term cash and low single-digit royalties, so the milestone schedule is what to price. 16 |
| M&A | Eaton / COL Group | Agreed September 25; €810 million ($923 million) enterprise value, bought from Oaktree Capital Management; close expected in the first quarter of 2027 | Oaktree Capital Management (seller) | COL Group forecasts 2027 sales of €250 million, which puts the multiple at roughly 3.2x forward revenue for medium-voltage grid equipment sold into data-centre and utility demand. 17 |
| Regulation | CFTC v. Cash FX Group S.A. and others | Complaint filed September 25 in the Middle District of Florida; over $950 million solicited, at least $406 million of participant losses | CFTC Division of Enforcement | The alleged instrument was a multilevel-marketing Ponzi promising up to 15% weekly returns on forex that was barely traded — restitution, disgorgement and bans sought. 18 |
| Regulation | SEC / OTC Link LLC | Settled order September 22; censure and a $575,000 civil penalty for Regulation SCI violations between August 2016 and March 2025 | SEC Division of Enforcement, Cyber and Emerging Technologies Unit | The penalty was expressly tied to repeated failure to remediate deficiencies that examinations staff had flagged several times, which is the part to carry into ATS governance reviews. 19 |
| Regulation | Federal Reserve stablecoin proposal | Proposed September 24 under the 2025 GENIUS Act; 60 days of comment from Federal Register publication | Federal Reserve Board | Full reserve backing in short-term Treasury bills, capital requirements, custody guidelines and a tailored application path for banks wanting to issue their own tokens. 20 |
| Regulation | Kalshi | Sixth Circuit ruled September 25 that Ohio and Tennessee may regulate Kalshi's event contracts under their gambling laws, vacating one injunction and upholding the denial of another | US Court of Appeals for the Sixth Circuit | The circuits now split — the Ninth Circuit sided with Nevada's oversight in August, the Third Circuit with Kalshi over New Jersey in April — which raises the odds the Supreme Court takes the question. 21 |
| Personnel | Berkshire Hathaway | Howard Buffett named chairman September 18; Warren Buffett becomes chairman emeritus, completing a succession begun when Greg Abel took the CEO role nine months earlier | — | The role is non-executive and scoped to preserving culture, so nothing about operating control changes; the governance read is that the transition is now complete at both levels. 22 |
| Financing | SoftBank Group (9984.T) | Priced September 24; $11.1 billion across five dollar and euro tranches; coupons of 8.625%, 9.25% and 9.75% on the dollar notes | — | The largest high-yield corporate bond sale on record, and it lands with SoftBank's holdings in Arm and OpenAI at three-quarters of group asset value and its five-year CDS above 400 basis points. 3 |
| Financing | Corporate refinancing wall | Reuters analysis of LSEG data published September 25: about $4.3 trillion of US non-financial corporate bonds mature between 2027 and 2031, with annual maturities rising from about $572 billion in 2027 to roughly $1.03 trillion in 2030 | PIMCO, Goldman Sachs (estimates cited) | High-yield maturities jump from about $68.5 billion in 2027 to $314.1 billion in 2029; CCC coupons could roughly double if refinanced at current index yields. 23 |
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.